现金管理进展公告 | 受托方 | 产品名称 | | 产品 | 金额 | 起始日 | 到期日 | 预计年化 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 类型 | （万元） | | | 收益率 | | 中信证券 | 信信向荣优享 27 | 号 | 稳健型 | 1,000.00 | 2025-10-16 | 2026-04-16 | 3.50% | | 浦发银行烟台 开发区支行 | 上信红宝石 T+N 期 | 第 116 | 稳健型 | 5,000.00 | 2025-10-20 | 2026-04-28 | 2.60% | | 中信证券 | 信信向荣优享 27 | 号 | 稳健型 | 6,000.00 | 2025-10-28 | 2026-04-29 | 3.50% | | 国投证券 | 安信资管周周盈 | 3 号 | 稳健型 | 10,000.00 | 2025-11-14 | \ | - | | 华夏银行烟台 自贸区支行 | 日日开理财产品 | 号 91 | 稳健型 | 6,000.00 | 2025-12-31 | 2026-01 ...

Core Viewpoint - The company is nearing the completion of the registration process for its calcium silicate bioceramic bone repair materials, with expectations to achieve certification within 2025. The active biological bone product is showing steady market promotion and revenue contribution, with plans for increased market penetration and revenue growth in the future [1]. Group 1 - The registration work for the calcium silicate bioceramic bone repair materials is close to completion [1] - The company will continue to monitor the registration progress and fulfill its information disclosure obligations [1] - The annual promotion and hospital admission volume of the active biological bone product is steadily increasing and meets expectations [1] Group 2 - The company aims to enhance product market coverage and revenue contribution levels through continued efforts in product promotion [1]

（文章来源：证券日报） 证券日报网讯 12月16日晚间，正海生物发布公告称，控股股东、实际控制人秘波海先生将其持有的公 司1600万股股份办理了解除质押业务。 ...

证券日报网讯12月16日，正海生物（300653）在互动平台回答投资者提问时表示，公司与江苏集萃研究 所合作开展的"重组生物活性蛋白产品的研究开发"项目正稳步推进中，不存在终止合作的情形。两项合 作开发项目具有不同的研发方向及技术路径，都是公司为丰富产品矩阵、提升长期竞争力的战略举措。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司先前与江苏集萃签署过关于重组蛋白的委托 开发合同进展如何？现在又与农科院签署委托开发合同是代表与之前的合作方终止合作么？还是双方同 时合作，分别承担不同的研发部分？ 正海生物（300653.SZ）12月16日在投资者互动平台表示，您好！公司与江苏集萃研究所合作开展的"重 组生物活性蛋白产品的研究开发"项目正稳步推进中，不存在终止合作的情形。两项合作开发项目具有 不同的研发方向及技术路径，都是公司为丰富产品矩阵、提升长期竞争力的战略举措。 ...

南财智讯12月16日电，正海生物公告，公司近日接到控股股东、实际控制人秘波海先生的通知，获悉秘 波海先生将其持有的公司部分股份办理了解除质押业务，本次解除质押股份数量为1600.00万股。截至 本公告披露日，秘波海及其一致行动人累计质押股份0股。 ...

正海生物公告，控股股东、实际控制人秘波海先生将其持有的1,600万股公司股份办理了解除质押业 务，占其所持股份比例26.25%，占公司总股本比例8.89%。此次解除质押的股份起始日为2022年6月22 日，解除日期为2025年12月15日，质权人为烟台银行股份有限公司开发支行。截至本公告披露日，秘波 海先生及其一致行动人累计质押股份为0股。 ...

控股股东、实际控制人部分股份解除质押的公告 证券代码：300653 证券简称：正海生物 公告编号：2025-048 烟台正海生物科技股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）近日接到控股股东、 实际控制人秘波海先生的通知，获悉秘波海先生将其持有的公司部分股份办理了 解除质押业务，具体事项如下： 一、股东股份解除质押的基本情况 | | 是否为控股 | 本次解除 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | 质押股份 | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | 名称 | 大股东及其 | 数量 | 比例 | 比例 | | | | | | 一致行动人 | （万股） | （%） | （%） | | | | | 秘波海 | 是 | 1,600 | 26.25 | 8.89 | 2022.6.22 | 2025. ...

Policy Developments - The National Medical Insurance Administration has issued a three-year action plan to enhance the efficiency of medical insurance fund settlement, aiming to complete annual settlements by March 31 each year starting in 2028, with settlement funds accounting for about 3% of the annual medical insurance fund allocation [2] Medical Device Approvals - Jiukang Bio has received a medical device registration certificate for its fructosamine testing kit, which is expected to enhance its product line in the in vitro diagnostic sector [5] - Yihuilong has obtained registration for its anti-phosphatidylserine/prothrombin IgM and IgG antibody testing kits, which will expand its automated chemiluminescence product line [6] - Kangzheng Pharmaceutical's oral JAK1 inhibitor, Povorcitinib, has been included in the "Breakthrough Therapy" list for treating non-segmental vitiligo in adults [7] Capital Market Activities - Fosun Pharma plans to invest a total of 1.412 billion yuan in Green Valley Pharmaceutical, acquiring a 53% stake through its subsidiary [9] - Paig Bio-Medical has announced a further extension of the lock-up period for cornerstone investors until April 30, 2026, and is raising approximately 296 million HKD for various strategic initiatives [10][11] Industry Developments - Nanjing has established a medical health merger and acquisition equity investment fund with a total investment of 800 million yuan, focusing on equity investment and asset management [13] - Zhenghai Bio has signed a 12 million yuan technical development contract with the Chinese Academy of Agricultural Sciences for the research and development of recombinant type III collagen products [14] - MicroPort Robotics has established a new medical technology company with a registered capital of 15 million yuan, focusing on the development and manufacturing of service robots [15] Public Opinion Alerts - Tongrentang has responded to allegations of false labeling regarding its Antarctic krill oil product, initiating legal action against the involved parties to protect consumer rights [17]

Policy Developments - The National Healthcare Security Administration (NHSA) has issued a three-year action plan to enhance the efficiency of medical insurance fund settlement, aiming to complete annual settlements by March 31 each year starting in 2028, with settlement funds accounting for about 3% of the annual medical insurance fund allocation [2] - This plan represents a systemic reform of the medical insurance system, addressing issues such as slow reimbursements for insured individuals and funding for medical institutions in the short term, while promoting scientific and refined management of medical insurance funds in the medium term [2] Medical Device Registration - The Deputy Director of the National Medical Products Administration, Lei Ping, attended a regional meeting on medical device registration management and conducted field research in Guangdong and Yunnan, emphasizing the need to align with the health demands of the people and plan for high-quality development in the medical device sector [3] Company Announcements - Jiukang Bio has received a medical device registration certificate for its fructosamine testing kit, which is expected to enhance its competitiveness in the in vitro diagnostic market, although future sales remain uncertain [5] - Yihuilong has obtained registration for its anti-phosphatidylserine/prothrombin IgM and IgG antibody testing kits, which will expand its product line in the autoimmune disease testing sector, with sales dependent on market conditions [6] - Kangzheng Pharmaceutical announced that its oral JAK1 inhibitor, Povorcitinib, has been included in the "Breakthrough Therapy" list for treating non-segmental vitiligo in adults [7] Capital Market Activities - Fosun Pharma plans to invest a total of 1.412 billion yuan in Green Valley Pharmaceutical, acquiring a 53% stake through its subsidiary [9] - Paig Bio Pharma-B has announced a further extension of the lock-up period for cornerstone investors until April 30, 2026, and is raising approximately 296 million HKD for various strategic initiatives [10] Industry Developments - A new medical health equity investment fund has been established in Nanjing with a total investment of 800 million yuan, focusing on private equity investments and asset management [12] - Zhenghai Bio has signed a 12 million yuan technology development contract with the Chinese Academy of Agricultural Sciences for the research and development of recombinant type III collagen products [13] - Beijing Weisi Weixiang Medical Technology Co., Ltd. has been established with a registered capital of 15 million yuan, focusing on the development and manufacturing of service robots [14] - Tongrentang Health has taken action against a product falsely labeled as produced by its subsidiary, initiating legal proceedings to protect consumer rights [15]